Work

Op0136 Metabolomic Serum Profiling Identifies Metabolites Linked to Kidney Damage Which Are Modulated by Anifrolumab in a Phase 2 Trial in Lupus Nephritis

Year: 2023

Type: conference-abstract

Source: Annals of the Rheumatic Diseases

DOI: 10.1136/annrheumdis-2023-eular.1569

Authors: D. Jayne, P. Gavin, E. Allman, C. Di Poto, X. Tian, S. Hess, M. Ramaswamy, M. Lazarus, P.Z. Brohawn, D. Muthas, A. Platt, H. Al-Mossawi, C. Lindholm, N. Ferrari

Institutions: University of Cambridge, AstraZeneca (United States), AstraZeneca (United Kingdom), AstraZeneca (Sweden)

Language: English

Topic: Systemic Lupus Erythematosus Research

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4379521287

Cites: 1

Cited by: 3

Related to: 10